Vantage Investment Advisors LLC Increases Holdings in Johnson & Johnson (JNJ)

Vantage Investment Advisors LLC raised its position in shares of Johnson & Johnson (NYSE:JNJ) by 1.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 80,582 shares of the company’s stock after purchasing an additional 1,309 shares during the quarter. Johnson & Johnson accounts for 2.6% of Vantage Investment Advisors LLC’s investment portfolio, making the stock its 6th biggest holding. Vantage Investment Advisors LLC’s holdings in Johnson & Johnson were worth $11,259,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in JNJ. Landmark Financial Advisors LLC increased its stake in shares of Johnson & Johnson by 0.4% in the second quarter. Landmark Financial Advisors LLC now owns 1,962 shares of the company’s stock worth $259,000 after acquiring an additional 7 shares during the last quarter. Premier Asset Management LLC increased its stake in shares of Johnson & Johnson by 0.4% in the second quarter. Premier Asset Management LLC now owns 2,749 shares of the company’s stock worth $363,000 after acquiring an additional 12 shares during the last quarter. Lbmc Investment Advisors LLC increased its stake in shares of Johnson & Johnson by 0.4% in the second quarter. Lbmc Investment Advisors LLC now owns 3,718 shares of the company’s stock worth $492,000 after acquiring an additional 14 shares during the last quarter. Halbert Hargrove Russell LLC increased its stake in shares of Johnson & Johnson by 0.4% in the second quarter. Halbert Hargrove Russell LLC now owns 3,523 shares of the company’s stock worth $466,000 after acquiring an additional 15 shares during the last quarter. Finally, Lenox Wealth Management Inc. increased its stake in shares of Johnson & Johnson by 1.7% in the second quarter. Lenox Wealth Management Inc. now owns 1,457 shares of the company’s stock worth $193,000 after acquiring an additional 24 shares during the last quarter. 67.23% of the stock is currently owned by institutional investors.

How to Become a New Pot Stock Millionaire

JNJ stock opened at $131.76 on Tuesday. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.41 and a quick ratio of 1.12. Johnson & Johnson has a 52-week low of $120.95 and a 52-week high of $148.32. The stock has a market cap of $350,440.66, a price-to-earnings ratio of 18.05, a PEG ratio of 2.08 and a beta of 0.74.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, January 23rd. The company reported $1.74 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.72 by $0.02. Johnson & Johnson had a net margin of 1.70% and a return on equity of 29.00%. The company had revenue of $20.20 billion during the quarter, compared to analysts’ expectations of $20.08 billion. During the same period in the prior year, the company earned $1.58 earnings per share. The business’s quarterly revenue was up 11.5% compared to the same quarter last year. equities analysts anticipate that Johnson & Johnson will post 8.11 EPS for the current fiscal year.

In other Johnson & Johnson news, VP Paulus Stoffels sold 155,342 shares of the company’s stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $129.86, for a total transaction of $20,172,712.12. Following the completion of the sale, the vice president now directly owns 357,906 shares in the company, valued at $46,477,673.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.22% of the stock is owned by corporate insiders.

A number of research firms have recently weighed in on JNJ. Jefferies Group set a $153.00 price target on shares of Johnson & Johnson and gave the stock a “buy” rating in a research note on Friday. Vetr downgraded shares of Johnson & Johnson from a “hold” rating to a “sell” rating and set a $124.55 price target on the stock. in a research note on Thursday, April 5th. Zacks Investment Research downgraded shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Monday, April 9th. Citigroup dropped their price target on shares of Johnson & Johnson from $150.00 to $146.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 27th. Finally, Morgan Stanley dropped their price target on shares of Johnson & Johnson from $148.00 to $143.00 and set an “equal weight” rating on the stock in a research note on Tuesday, April 10th. Five research analysts have rated the stock with a sell rating, nine have assigned a hold rating and eight have assigned a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $144.03.

TRADEMARK VIOLATION NOTICE: “Vantage Investment Advisors LLC Increases Holdings in Johnson & Johnson (JNJ)” was posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be read at https://www.chaffeybreeze.com/2018/04/17/vantage-investment-advisors-llc-increases-holdings-in-johnson-johnson-jnj.html.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply